HRA006643
Title:
Determinants of neoadjuvant response and resistance in advanced clear cell renal cell carcinoma
Release date:
2025-08-19
Description:
With immunotherapy-based combination (ICB) has been recommended as first-line treatment for advanced RCC, Labbate et al. initially reported a case of complete response of an extensive vena cava tumor thrombus with neoadjuvant immunotherapy. Though the safety and feasibility has been confirmed by following studies, the evidence was based on case report and series. Due to high objective response rate of ICB than TKI in advanced RCC, we hypothesized that the ICB would yield a higher reduction in level of inferior vena cave tumor thrombus (IVC-TT). This Phase 2 pilot study evaluated the efficacy and safety of neoadjuvant toripalimab plus axitinib for RCC with IVC-TT.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
renal cell carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Neoadjuvant therapy for RCC
Contact person:
ci Weimin
Email:
ciwm@foxmail.com
Description:
With immunotherapy-based combination (ICB) has been recommended as first-line treatment for advanced RCC, Labbate et al. initially reported a case of complete response of an extensive vena cava tumor thrombus with neoadjuvant immunotherapy. Though the safety and feasibility has been confirmed by following studies, the evidence was based on case report and series. Due to high objective response rate of ICB than TKI in advanced RCC, we hypothesized that the ICB would yield a higher reduction in level of inferior vena cave tumor thrombus (IVC-TT). This Phase 2 pilot study evaluated the efficacy and safety of neoadjuvant toripalimab plus axitinib for RCC with IVC-TT.
Individuals & samples
Submitter:   ci Weimin / ciwm@foxmail.com
Organization:   The Third Medical Center of Chinese PLA General Hospital
Submission date:   2024-02-03
Requests:   4